Harmony Biosciences (NASDAQ:HRMY - Get Free Report)'s stock had its "outperform" rating reiterated by research analysts at Raymond James in a research report issued on Thursday, Benzinga reports. They currently have a $40.00 target price on the stock. Raymond James' price objective suggests a…
Continue reading...